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Summary
Cerebral microbleeds (CMB) are increasingly recognized neuroimaging findings, occurring with
cerebrovascular disease, dementia, and normal aging. Recent years have seen substantial progress,
particularly in developing newer MRI methodologies for CMB detection and applying them to
population-based elderly samples. This review focuses on these recent developments and their
impact on two major questions: how CMB are detected, and how they should be interpreted. There
is now ample evidence that prevalence and number of detected CMB varies with MRI
characteristics such as pulse sequence, sequence parameters, spatial resolution, magnetic field
strength, and post-processing, underlining the importance of MRI technique in interpreting
studies. Recent investigations using sensitive techniques find the prevalence of CMB detected in
community-dwelling elderly to be surprisingly high. We propose procedural guidelines for
identifying CMB and suggest possible future approaches for elucidating the role of these common
lesions as markers for, and potential contributors to, small vessel brain disease.
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Introduction
Small foci of chronic blood products in normal (or near normal) brain tissue, designated here
as cerebral microbleeds (CMB), have been an increasingly recognized entity since the
widespread application in the early to mid 1990s of magnetic resonance imaging (MRI)
techniques tailored to detect magnetic susceptibility.1,2 Recent years of investigation into
CMB have seen several notable developments. Advances in MRI software and hardware
have yielded striking improvements in sensitivity, leading to increased detection of CMB as
well as evolution of the criteria used for their identification. A second area of rapid progress
has been application of sensitive MRI imaging to the community-dwelling elderly
population as a whole, where the prevalence of detected CMB appears to be as high as 11.1
to 23.5%.3,4 Population-based MRI analyses have also suggested intriguing connections
between normal aging and asymptomatic stages of age-associated small vessel diseases such
as hypertensive vasculopathy and cerebral amyloid angiopathy (CAA). Thus despite the
appearance of several comprehensive reviews of CMB,5-9 these advances warrant a new
assessment of emerging technical aspects of image acquisition, specific criteria for lesion
identification, and recent data from population-based analysis.
Basis for review and identification of references
Material in this review reflects the consensus of a conference entitled “Cerebral
Microbleeds: Detection and Definition” held by the Microbleed Study Group (see
Acknowledgments for list of additional participants) on April 12, 2008 in Chicago, USA.
This material was supported and supplemented by references identified by searches of
PubMed from 1966 to October 2008 using the terms 1) “microbleed(s),”
“microh(a)emorrhage(s),” or “petechial h(a)emorrhage(s)” or 2) “gradient-echo,” “T2*” or
“susceptibility” in conjunction with “h(a)emorrhage(s).” References were also identified
from the bibliography of identified articles and the authors’ files. Only papers in English or
with available English translations of relevant data were considered. The final reference list
includes papers judged by the authors to pertain to the specific topics addressed in this
review.
CMB: How to Detect
The concept of CMB is primarily a radiological construct (i.e. describing small MRI signal
voids), but one meant to represent a specific underlying microscopic pathology (i.e.
perivascular collections of hemosiderin deposits, representing foci of past hemorrhage). The
following section reviews advances in MRI methods for CMB detection, the criteria used to
include or exclude MRI lesions as bona fide CMB, and what is known of the correlation
between MRI and underlying histopathology.
MRI Parameters
The hemosiderin deposits that comprise CMB10 are superparamagnetic and thus have
considerable internal magnetization when brought into the magnetic field of MRI, a property
defined as magnetic susceptibility. Internal magnetization generates local inhomogeneity in
the magnetic field surrounding the CMB, leading to faster decay of the local MRI signal,
designated the susceptibility effect. On MRI sequences that are particularly sensitive to
susceptibility effects, CMB will appear as black or hypointense lesions (signal voids).
The MRI parameters of greatest influence on CMB detection are pulse sequence, sequence
parameters, spatial resolution, magnetic field strength, and post-processing. The potential
effect of these factors on microbleed conspicuity and detection is discussed below. Limited
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experience applying various MRI parameters to population-based studies (Table 1)2-4,11-13
suggests that choice of methods has substantial impact on the measured prevalence of CMB.
Among available pulse sequences, T2*-weighted gradient-recalled echo (GRE) MRI lacking
the 180° refocusing pulse characteristic of spin-echo (SE) or fast-spin echo techniques14 is
highly sensitive to the susceptibility effect. T2*-weighted GRE sequences tailored to image
susceptibility effects (the term T2*-weighted MRI is used below) are thus substantially more
sensitive to CMB than T2-weighted SE sequences.2,15-17 The areas of low intensity that
appear on T2*-weighted MRI are larger than the corresponding hemosiderin deposits,
representing the so-called “blooming” effect (Fig. 1A). It is important to note that because
extent of blooming varies with MRI parameters, the size of the measured signal void will
depend on factors beyond the size of the corresponding histopathological CMB. Echo-planar
GRE imaging, in which an entire image is obtained from a single radiofrequency pulse
excitation, can potentially lead to ultrafast acquisition with comparable CMB conspicuity,18
but possibly at the cost of increased artifact and distortion.19
The sequence parameter that particularly affects sensitivity to magnetic susceptibility in
T2*-weighted MRI is echo time (TE). TEs of 25 to 50 ms have generally been applied
(Table 1),2,16,20 with longer TEs allowing more time for dephasing and consequently
enlarging the susceptibility effect.21 Use of longer TE can lead to a trade-off in image
quality, however, because of decay of transverse magnetization.22
Higher spatial resolution (in particular the use of thinner scanning sections) offers the
possibility of minimizing the partial-volume averaging that might interfere with CMB
detection. Using a three-dimensional (3D) Fourier transform technique in T2*-weighted
MRI allows acquisition of very thin image slices at high signal to noise ratio. Recently,
application of 3D T2*-weighted MRI at sub-millimeter spatial resolution (reconstructed
voxel size of 0.5 × 0.5 × 0.8 mm3) was shown to detect more CMB when compared to
conventional 2D GRE at lower resolution (Fig. 1B).20 Another study comparing 1.5 mm to 5
mm slice thicknesses found that individual CMB identified in CAA subjects had
approximately double the contrast index (a measure of conspicuity) when imaged with
thinner slices than with thicker slices.23 The longer scan times associated with scanning at
small voxel sizes in 3D T2*-weighted MRI can be reduced to acceptable limits through
acceleration by parallel imaging.20
Increased magnetic field strength, 3 Tesla (T) or even higher, appears to improve CMB
conspicuity.23-26 Susceptibility effect is higher at higher magnetic field strength and
blooming effects are therefore predicted to be greater.
Finally, use of image post-processing techniques may further enhance the contrast between
brain tissue and hemosiderin deposits. T2*-effects can be augmented by multiplying
magnitude (reflecting loss of signal) with phase (reflecting hemosiderin-related signal phase
shift), a technique referred to as susceptibility-weighted imaging (SWI).27 Application of
SWI to CMB imaging appears promising,28 yielding substantially higher contrast index for
individual CMB relative to conventional T2*-weighted MRI.23 The added value of this
technique over higher field strength and smaller voxel sizes remains to be determined.
Lesion Parameters, Mimics, and Detection Criteria
Although precise definitions of the MRI lesions that should be classified as CMB have
varied,7 there is general agreement that they represent small areas of signal void with
associated blooming, excluding larger hematomas (or “macrobleeds”), specific secondary
causes of bleeding, and non-hemorrhagic causes of signal void. This starting point leaves
room for several unaddressed questions, in particular defining operational rules needed to
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differentiate CMB from macrobleeds, hemorrhagic and non-hemorrhagic CMB mimics. We
discuss relevant considerations and possible approaches to these questions below.
Various size cut-points have been used for discriminating microbleeds from macrobleeds,
typically ranging up to a maximum diameter of 5 to 10 mm and in some studies a minimum
of 2 mm (summarized in reference7). Recent insights, however, suggest several reasons for
deemphasizing precise size criteria. First, the size of a given CMB on MRI depends on
imaging parameters such as field strength and sequence as noted above. This consideration
as well as the difficulty in implementing identical pulse sequences on different MRI systems
substantially complicates attempts to compare CMB size across studies. A second
consideration is that microbleeds and macrobleeds may fall in a naturally bimodal size
distribution that does not strongly depend on the precise cut-point chosen to differentiate
them. A recent analysis of lesion volumes for 163 hemorrhages seen on routine clinical
(1.5T, 5 mm slice thickness) T2*-weighted MRI among 46 subjects presenting with
probable CAA found not a single continuum of hemorrhage sizes, but rather a distinctly
bimodal distribution with separate widely spaced peaks representing the microbleeds and
macrobleeds.29 Interestingly, the cut-point that best divided the microbleed and macrobleed
peaks corresponded to a diameter of 5.7 mm, similar to the 5 to 10 mm maximum
conventionally used.5-7
The major mimics of CMB are discussed below and illustrated in Fig. 2. They arise in large
part from the sensitivity of T2*-weighted MRI to paramagnetic substances other than
hemosiderin, including calcifications, iron deposits, or deoxyhemoglobin. Such artifacts are
expected to be more problematic using methods with higher sensitivity to susceptibility
artifact such as SWI or higher field strength MRI.
• Both calcium and iron deposits may appear as small foci of low signal intensity on
T2*-weighted MRI (Fig. 2A). These abnormalities are usually found bilaterally in
the basal ganglia, although calcification can also occur in the choroid plexus, pineal
gland, and lobar locations. CT can help identify suspected calcification, though its
routine use is infrequent (6 of 53 reviewed studies).7
• Flow voids in pial blood vessels caught in cross-section in cortical sulci can be
distinguished from CMB by their sulcal location, their equal visibility on T2-
weighted SE and GRE sequences (as arterial flow voids do not generate a blooming
effect), and their linear structure when examined over contiguous slices,
particularly evident at smaller slice thickness. The presence of paramagnetic
deoxyhemoglobin in cerebral venules produces its own blooming effect, however,
requiring the reader to rely on their tubular structure for differentiating them from
CMB (Fig. 2B). The distinction from flow voids can also be difficult when a CMB
appears immediately adjacent to a small vessel, but is suggested by the lesion’s
termination as a blind end rather than continuing linearly as a vessel branch.
• Partial volume artifact from bone (with associated susceptibility artifact from air in
the sinuses) may obscure CMB or confuse their interpretation, especially in the
temporal and frontal lobes because of the orbit and mastoid bones (Fig. 2C).
• Cavernous malformations can be considered as a secondary cause of CMB
(particularly the small “type IV” cavernous malformations30), but are
distinguishable from typical primary CMB by the appearance on both T1- and T2-
weighted sequences of stagnant blood in the sinusoidal lumen, extravasated blood
at varying stages of degradation and the characteristic hemosiderin rim31 (Fig. 2D).
This CMB mimic can itself be mimicked by the “ringing artifact” seen on T2*-
weighted MRI (Fig. 1A), representing increased signal within flow void. Ringing
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artifact is typically absent on T2-weighted SE MRI, highlighting the importance of
incorporating SE in conjunction with T2*-weighted MRI.
• Metastatic melanoma in the brain can appear hypointense on T2*-weighted MRI,32
a result of both the presence of melanin and the tendency of these tumors to bleed.
These lesions can often be distinguished from primary CMB by the concomitant
presence of T1 hyperintensity (caused by the melanin) or of surrounding edema
(particularly following recent intra-tumor hemorrhage), but small non-edematous
lesions may mimic primary CMB.
• Diffuse axonal injury following head trauma is another potential secondary cause
of CMB, distinguishable from primary CMB by the clinical history and
concomitant imaging abnormalities.33
Based on these considerations, it is reasonable to suggest working criteria for CMB
detection (Table 2). For designation as CMB, a signal should be black or very hypointense
on T2*-weighted MRI, round or ovoid (excluding tubular or linear structures such as those
representing vessels or a resorbed macrobleed), blooming (larger or more conspicuous on
GRE than SE MRI), devoid of T1- or T2-weighted hyperintensity (such as cavernous
malformation, hemorrhagic infarct, or melanotic melanoma), and at least half surrounded by
brain parenchyma (permitting superficial CMB as seen in CAA). Other mimics such as
mineralization of the basal ganglia or diffuse axonal injury are excluded based on
appearance or clinical history. As noted above, we suggest that size may be relatively
unimportant for correctly categorizing lesions that otherwise meet these criteria and should
be applied conservatively if at all.
A recognized consequence of the differential diagnosis of CMB is disagreement about their
presence and numbers within and between raters. Coefficients of correlation between two
raters’ quantifications of CMB number have been >0.8, but inter-rater reliabilities about the
presence of ≥1 CMB in studies using conventional T2*-weighted MRI have been poorer
(kappa 0.33 to 0.88),34 probably because of difficulties in detection and certainty about one
or a few lesions. Early investigations suggest that standardized rating instruments may be
helpful to improve inter-rater reliability.34
Radiological-Pathological Correlation
MRI carries obvious limitations relative to histopathological examination for investigating
CMB, including the potential imaging artifacts described above as well as inability to
provide microscopic evidence for specific tissue or small vessel pathologies. In interpreting
MRI-pathological correlation studies, however, it is also important to recognize the basic
limitation of histopathology: the practical impossibility of examining the entire brain in
microscopic section. This limitation is particularly relevant to identification of CMB, lesions
near the lower limits of gross visual detection and small enough to be fully contained within
even a thin (e.g. 5 mm) brain slice without being exposed to the examining pathologist for
sectioning. Conversely, the ability of modern MRI techniques to sample the full brain at
spatial resolutions of 1 mm or less raises the possibility that MRI may ultimately prove
substantially more sensitive than histopathology for CMB detection.
Radiological-pathological correlation studies of CMB10,35,36 have been able to link the
majority of signal voids seen on T2*-weighted MRI with microscopic hemorrhagic foci.
Fazekas and colleagues reported that 21 hypointense lesions seen on pre- or post-mortem
T2*-weighted MRI of 11 autopsied brains corresponded pathologically to clusters of
hemosiderin-laden macrophages.10 Similar pathological findings were observed in 8 of 9
T2*-weighted MRI hypointense lesions identified in 1 brain by Tatsumi and colleagues
using post-mortem T2*-weighted MRI of brain slices to guide their search.36
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In these studies of conventional T2*-weighted MRI methods, sensitivity of MRI and
histopathologic examination for CMB detection appeared comparable. In the study by
Fazekas and colleagues,10 T2*-weighted MRI (using 5 mm slices and 0.5 mm inter-slice
gap) detected 13 lesions not seen pathologically whereas histopathologic exam identified 20
additional CMB not detected by T2*-weighted MRI. These MRI-negative lesions tended to
be smaller than the MRI-positive lesions (described as “only a few perivascular
hemosiderin-laden macrophages”) and in retrospect, may represent the class of CMB
currently being uncovered by the more sensitive modified T2*-weighted methods. Further
radiological-pathological correlation studies using these more sensitive imaging methods
will be needed to determine whether they indeed detect a higher proportion of
histopathological microbleeds than conventional T2*-weighted MRI.
The specificity of T2*-weighted MRI for CMB appears to be fairly high. Among the 14
MRI lesions in these two studies10,36 not identified with histopathological microbleeds, only
1 corresponded to a potential CMB mimic, described as a “vascular pseudocalcification.”36
Again, it will be important for future studies using newer T2*-weighted MRI methods to
repeat these MRI-autopsy correlation analyses to confirm that the sensitive imaging
techniques maintain a relatively high specificity for CMB.
CMB: How to Interpret
Markers of disease
1. Vascular pathology—One approach to interpreting CMB is as a marker of
accompanying vascular pathology. Histopathologic analyses of the vessels associated with
CMB, performed primarily in brains with hemorrhagic stroke, have generally identified two
types of vascular pathologies: hypertensive vasculopathy and CAA.10,35,37 Among the 11
brains examined by Fazekas and colleagues10 for example, advanced hypertensive
lipohyalinotic changes were seen in 9 and CAA in 2. These two pathologies are typically
characterized by different patterns of microbleed distribution: CMB associated with
hypertensive vasculopathy tend to occur in basal ganglia, thalamus, brainstem, and
cerebellum,10 whereas advanced CAA is associated with a lobar (or less commonly
cerebellar) distribution (Fig. 3).37 The lobar distribution of CAA-related CMB is consistent
with the distribution of CAA vascular pathology38 and has served as the basis for the
radiologic diagnosis of probable CAA in hemorrhagic stroke patients according to the
pathologically validated Boston criteria.37 The Boston criteria for probable CAA specify
that this diagnosis cannot be made if any CMB are located in basal ganglia, thalamus, or
brainstem, regions atypical for CAA pathology. Within the lobar brain compartment, CAA-
related CMB39 and the underlying CAA pathology38,40 appear to favor posterior cortical
regions, particularly the occipital lobe.
The pathological factors that determine whether a particular bleeding event will result in a
microbleed versus a macrobleed is another focus of ongoing investigation. The observed
bimodal distribution of hemorrhage volumes29 raises the possibility of a threshold
mechanism, whereby a bleed can either remain small or reach a critical size that causes it to
continue to enlarge fully into the macrobleed range. This possibility echoes Fisher’s
suggestion in 1971 that macrobleeds occur in “avalanche or domino style”41 when bleeding
from one ruptured vessel causes secondary rupture of surrounding arteries. Fisher based this
idea on the observation that a serially sectioned acute hypertensive pontine hemorrhage was
surrounded by 24 or more sites of recent arterial rupture in vessels without advanced
lipohyalinotic changes, apparently representing sites of mechanical rupture secondary to the
primary bleed. This now classic study offers an intriguing framework for future
investigations of how CMB might be related to their larger symptomatic counterparts.
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2. Association with disease-related risk factors—A second approach to CMB
interpretation is analyzing their associations with particular risk factors and disease states.
Studies on correlates of CMB in hemorrhagic stroke patients, ischemic stroke patients, and
population-based, community-dwelling elderly (see Table 1) have been extensively
reviewed.5-7 Hypertension appears to be the most consistent predictor of CMB, with odds
ratios averaged across studies in stroke patients and healthy adults of 2.3 and 3.9.7 An
association between CMB and hypertension is further supported by relationships of CMB
prevalence to measured blood pressures,2,4 lacunar infarcts or white matter
lesions,2,4,13,42-48 retinal microvascular lesions,49 and left ventricular hypertrophy.50 These
observations suggest that the blood pressure-related vascular pathologies that can produce
larger, symptomatic intracerebral hemorrhage (ICH) can also give rise to CMB. Other risk
factors for ICH such as age2-4,12,13 and low serum cholesterol concentration4,51 also appear
to associate with higher prevalence or number of CMB. The association between low
cholesterol and CMB is particularly intriguing in light of recent data showing increased risk
of symptomatic ICH in stroke patients randomized to high-dose atorvastatin.52 This
increased risk was independent of low-density lipoprotein cholesterol level,53 however,
suggesting that mechanisms other than lipid lowering might be responsible.
Recent population-based data offer some support for the possibility raised above that CMB
location may correlate with specific vascular pathologies (i.e. deep hemispheric or
infratentorial CMB suggesting hypertensive vasculopathy, a strictly lobar distribution
suggesting CAA). Analysis of APOE genotype in subjects from the Rotterdam Scan Study
subdivided according to CMB distribution found an association with the APOE ε4 allele
pertaining only to the subgroup with isolated lobar CMB (odds ratio for APOE ε4 carriers of
1.87, 95% confidence interval 1.25 to 2.81) and not the subgroup with deep hemispheric or
infratentorial CMB (odds ratio 1.17, 95% confidence interval 0.70 to 1.93).4 Given the
relationship between APOE ε4 and CAA,54,55 these results raise the interesting possibility
that isolated lobar CMB (a subgroup accounting for 58% of CMB-positive subjects in the
Rotterdam study4) may often reflect the presence of advanced CAA. In the same study,
systolic blood pressure, severe hypertension, and lacunar infarcts appeared more closely
linked to deep or infratentorial CMB,4 suggesting hypertensive vasculopathy as the
predominant underlying disease in this subgroup. These intriguing findings still await
confirmation in other population-based studies of older subjects. The Framingham Study of
relatively younger subjects scanned at a lower magnetic field strength (see Table 1) found
no association with APOE genotype among all CMB or lobar-only CMB subjects,13
whereas the AGES Reykjavik study of older subjects reported a significant
overrepresentation of the APOE ε4/ε4 genotype among all subjects with CMB (4.2% versus
1.8%, p=0.01).3
Determining whether a lobar distribution of CMB can be used to diagnose CAA in the
general population may ultimately require population-based MRI-autopsy correlation
studies. Previously reported population-based clinical-autopsy series have found CAA to be
a common neuropathological finding,40,56,57 but have not yet examined its correlation with
CMB detected on pre-mortem MRI scans.
3. Risk for hemorrhagic stroke—As markers of underlying hemorrhage-prone vascular
pathology, CMB might be expected to predict future risk of symptomatic intracerebral
hemorrhage. Studies of prospectively followed survivors of lobar ICH58 and ischemic
stroke59 suggest this is the case, at least post-stroke. Among 94 survivors of primary lobar
hemorrhage, higher total numbers of hemorrhages (the presenting ICH plus other micro- and
macrobleeds detected by T2*-weighted MRI at baseline) predicted increased risk of future
symptomatic hemorrhage: 3-year cumulative risk of 14% for those with only a single
hemorrhage, 17% for 2 lesions, 38% for 3 to 5, and 51% for ≥6.58 Similarly, among 908
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ischemic stroke survivors, the risk of subsequent hemorrhagic stroke over 26 months of
follow-up increased from 0.6% for those with no accompanying CMB to 1.9% with 1
microbleed, 4.6% with 2 to 4, and 7.6% for ≥5.59 Studies of ischemic stroke patients have
also suggested possible links between CMB and spontaneous or thrombolysis-associated
post-stroke bleeding (primarily into the infarcted territory),60,61 although these findings have
been questioned by recent analyses.62,63 The predictive value of CMB in people without
previous stroke is currently unknown and represents a key issue to be addressed by ongoing
longitudinal population studies.
The association between CMB and future symptomatic ICH raises the question of whether
the increased risk might be great enough to tip the risk-benefit calculation away from
anticoagulation in situations where it is otherwise beneficial, such as prevention of
thromboembolism in individuals with atrial fibrillation. A recent decision analysis using
current risk estimates suggested that anticoagulation would still be beneficial in patients
with asymptomatic CMB,64 contrasting with the suggestion that anticoagulation should be
avoided following symptomatic CAA-related ICH.65 For antiplatelet agents, longitudinal
data from 127 subjects with symptomatic lobar ICH (27 on antiplatelet treatment) and 80
subjects with symptomatic deep hemispheric ICH (19 on antiplatelet treatment) did not find
an increase in recurrent ICH, although a modestly elevated risk could not be excluded.66 The
question of how CMB should affect antithrombotic use remains an active area of
investigation, particularly in light of broadening indications for these agents.
Contributors to Neurologic Dysfunction
In addition to their role as markers of underlying disease, CMB could also have direct
effects on neurologic function, cognition, and disability. Indeed, neuropathological analyses
of CMB generally find these lesions to be associated with some degree of surrounding tissue
damage,10,35,36 offering a potential mechanism for brain dysfunction.
The possibility that CMB contribute to clinical deficits is supported by findings from the
prospective study of 94 survivors of primary lobar ICH cited above, where higher numbers
of hemorrhages at baseline was also associated with increased incidence of future cognitive
impairment, functional dependence or death at follow-up: 3-year cumulative risk of 16% for
those with 1 hemorrhage, 20% for 2 hemorrhages, 51% for 3 to 5, and 52% for ≥6.58 CMB
have also been associated with clinical disability in the hereditary small-vessel disease
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL).67,68 In a two-center cohort study of 147 patients with CADASIL, the number
of CMB was independently associated with functional dependence (defined as modified
Rankin score ≥3) with an odds ratio per additional microbleed of 1.16 (95% confidence
interval 1.01 to 1.34, p=0.034) after adjustment for other confounding variables.68
Multivariable analysis to define correlates of cognition did not, however, find a similar
independent association with CMB. Finally, a small case-control study of patients with
ischemic stroke or TIA found that individuals with CMB performed significantly worse than
those without on standard tests of executive function.69 Although each of these studies
attempted to control for potential confounders, the association of CMB with other markers
of small vessel injury such as lacunar infarcts and white matter damage points to the need
for confirmation in larger studies with greater statistical power as well as studies of
individuals without prior stroke.
If CMB indeed have direct effects on brain function (rather than simply marking the
presence of other cerebrovascular pathologies), one would expect CMB location to play a
role. In analyses of the two-center CADASIL cohort, CMB in the caudate were
independently associated with lower global cognitive scores (based on the Mattis dementia
rating scale; p=0.027) and CMB in the frontal lobes showed a trend toward lower global
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cognitive scores (p=0.056).70 Similarly, the small study of stroke/TIA subjects suggested
more microbleeds in the frontal lobes and basal ganglia of those with executive dysfunction
compared to those without.69 Detailed anatomical mapping of CMB, as has been performed
with other MRI lesions,71 would seem a promising approach for future clinical-MRI
correlation studies. Given the widespread distribution of CMB and their frequent association
with other small vessel-related pathologies, however, such studies will again need to be both
large and carefully controlled.
Recommendations and Future Directions
The considerations outlined above summarize considerable progress over just a short period
of intensive investigation into the identification and interpretation of CMB. Below is a
tentative list of conclusions and recommendations for future studies (the latter shown in bold
type).
1. Cerebral microbleeds appear to be a well-defined pathological lesion detectable by
T2*-weighted MRI techniques with high sensitivity (particularly using newer MRI
methods), high reliability (with careful image interpretation and consideration of
CMB mimics), and high specificity (demonstrated for conventional T2*-weighted
MRI, still to be established for the newer methods methods). The full brain
coverage afforded by MRI likely renders neuroimaging a more sensitive method for
CMB detection than practical histopathologic techniques.
2. Choice of T2*-weighted MRI methods (including sequence parameters, spatial
resolution, field strength, and post-processing) has large effects on the prevalence
and number of detected CMB and thus on overall study sensitivity. Although it is
premature to specify a standard sequence for all future studies, such a standard will
evolve over the coming years and will likely include thin imaging slices. The
process of reaching a common standard will be accelerated by further side-by-side
comparisons of individual subjects with CMB imaged using varying MRI
methods.20,23
3. All studies of CMB should specify the above imaging parameters and should
follow systematic rules or standardized rating instruments for excluding CMB
mimics. These factors should presumably be held constant in longitudinal studies
aiming for repeated measurements. Choice of precise size parameters for CMB
does not appear to have major effects on their detection.
4. Using advanced T2*-weighted MRI methods, population-based studies show CMB
to be very common lesions in community-dwelling elderly, with prevalences on the
order of 10 to 25%.
5. Accumulating evidence suggests that CMB might be reflective of specific
underlying vascular pathologies, in particular hypertensive vasculopathy (for CMB
in deep hemispheric or infratentorial locations) or cerebral amyloid angiopathy (for
CMB restricted to lobar locations). Their presence and number may also reflect the
severity of these hemorrhage-prone pathologies and thus predict risk of future
symptomatic intracerebral hemorrhage. Future studies of CMB-positive subjects
should consider separate subgroup analyses according to CMB location (deep
hemispheric/infratentorial versus lobar only; Fig. 3).
6. The evidence that CMB directly disrupt brain functioning is less clear and will
require carefully controlled studies to disentangle their contribution from that of
other small-vessel brain lesions such as lacunar infarcts and white matter
hyperintensities that frequently accompany CMB.
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7. The immediate future in CMB research is likely to see evolution of a shared set of
standards for their detection that will allow fruitful cross-study comparisons and
enable robust longitudinal data collection. Determining whether CMB should affect
clinical decision-making, identifying their interrelationship with other
manifestations of small-vessel disease, and dissecting out their independent
contribution to vascular cognitive and neurologic dysfunction are key longer-term
goals.
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Figure 1. Increased conspicuity of CMB with T2*-weighted MRI techniques
Panel A compares T2 fast SE (left) and T2*-weighted MRI (right) imaging of the same
CMB, shown at high magnification. The blooming effect is demonstrated by the larger area
of signal void on the T2*-weighted MRI compared to the fast SE image. The GRE image
also illustrates the ringing artifact as an area of high signal within the signal void. Panel B
compares images obtained at corresponding axial levels using a conventional 2D sequence
T2*-weighted MRI (left; TR/TE 775/20, flip angle 25°, voxel size 0.5×0.5×5 mm3) versus
an accelerated 3D T2*-weighted MRI sequence (right; TR/TE 45/31, flip angle 13°, voxel
size 0.5×0.5×0.8 mm3). Magnifications of matching brain regions are shown at bottom. The
3D T2*-weighted MRI image demonstrates three CMB in lobar locations (white arrows)
that are not or barely discernible on the 2D T2*-weighted MRI image.
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Figure 2. CMB confounds and mimics
Panel A, left is an axial T2*-weighted MRI image showing a calcification in the left
hemisphere (arrow) mimicking a CMB. The CT scan (right) demonstrates this lesion as an
area of very high density. Note that the MRI also shows a right hemispheric hypointense
lesion (arrowhead) surrounded by hyperintense signal, corresponding to the tip of a
spontaneous intracerebral hemorrhage demonstrated on the CT image. Panel B uses a
minimum intensity projection of an axial T2*-weighted MRI image (4 mm slab) to illustrate
CMB (white arrows) in proximity to vessel flow voids on the brain surface. The vessels can
be distinguished from CMB by their linear shape, while the CMB appear as blind-ended
round or ovoid structures. Panel C is an axial T2*-weighted MRI image demonstrating
partial volume artifact as a potential CMB mimic. The axial T2*-weighted MRI image on
the left shows a round focus of signal loss (arrow) that could be interpreted as a left temporal
CMB. The image just caudal to this (right) indicates that this hypointensity is due to partial
volume artifact from the adjacent left sphenoid bone (arrowhead). Panel D shows axial
proton density-weighted (left), T1-weighted (middle) and T2*-weighted MRI (right) images
depicting a cavernous malformation (white arrows) mimicking a CMB. The hyperintense
signal within the hypointense rim on proton density or T2-weighted sequences helps
distinguish these lesions from CMB.
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Figure 3. Deep hemispheric and isolated lobar patterns of CMB distribution
The left panel represents a T2*-weighted MRI image from an 84-year-old woman with long-
standing hypertension. CMB are present predominantly in the bilateral thalamus, putamen,
caudate, and cerebellum, with only a small number in lobar brain regions (not shown in this
image). The right panel is from a 77-year-old woman without hypertension. CMB are
present only in lobar brain regions, meeting criteria for probable CAA.37
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Table 2
Recommended Criteria for CMB Identification
1 Black on T2*-weighted MRI
2 Round or ovoid (rather than linear)
3 Blooming on T2*-weighted MRI
4 Devoid of signal hyperintensity on T1- or T2-weighted sequences
5 At least half surrounded by brain parenchyma
6 Distinct from other potential mimics such as iron/calcium deposits, bone, or vessel flow voids
7 Clinical history excluding traumatic diffuse axonal injury
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